Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
Natalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAAbstract: The improvement in outcomes of adult patients with acute lymphoblastic leukemia (ALL) has been modest,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-04-01
|
| Series: | Journal of Blood Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/inotuzumab-ozogamicin-in-the-treatment-of-relapsedrefractory-acute-b-c-peer-reviewed-article-JBM |
| _version_ | 1818312205138919424 |
|---|---|
| author | Uy N Nadeau M Stahl M Zeidan AM |
| author_facet | Uy N Nadeau M Stahl M Zeidan AM |
| author_sort | Uy N |
| collection | DOAJ |
| description | Natalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAAbstract: The improvement in outcomes of adult patients with acute lymphoblastic leukemia (ALL) has been modest, with the exception of Philadelphia chromosome-positive disease, despite advances in supportive care and stem cell transplantation. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products are changing the management of B-ALL, which traditionally relied on chemotherapy-based approaches. Inotuzumab ozogamicin is a humanized CD22 monoclonal antibody linked to the cytotoxic agent calicheamicin. CD22 is expressed on leukemic blasts in >90% of ALL patients, and inotuzumab ozogamicin has shown excellent clinical activity even among heavily pretreated relapsed/refractory (R/R) B-ALL patients and elderly B-ALL patients. Clinical trials have shown superior survival with the drug over chemotherapy-based approaches in the first- or second-line salvage therapy for relapsed B-ALL as monotherapy. Currently, new trials are evaluating inotuzumab ozogamicin in the frontline setting in combination-based approaches. In this review, we summarize the preclinical and clinical data of inotuzumab ozogamicin in R/R B-ALL and foresee the future use of this drug in the clinic.Keywords: inotuzumab ozogamicin, CD22, monoclonal antibodies, acute lymphoblastic leukemia, antibody-drug conjugate |
| first_indexed | 2024-12-13T08:14:09Z |
| format | Article |
| id | doaj.art-8cda8204d2364c34a15a1e3618210b0e |
| institution | Directory Open Access Journal |
| issn | 1179-2736 |
| language | English |
| last_indexed | 2024-12-13T08:14:09Z |
| publishDate | 2018-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Blood Medicine |
| spelling | doaj.art-8cda8204d2364c34a15a1e3618210b0e2022-12-21T23:54:09ZengDove Medical PressJournal of Blood Medicine1179-27362018-04-01Volume 9677437784Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemiaUy NNadeau MStahl MZeidan AMNatalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAAbstract: The improvement in outcomes of adult patients with acute lymphoblastic leukemia (ALL) has been modest, with the exception of Philadelphia chromosome-positive disease, despite advances in supportive care and stem cell transplantation. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products are changing the management of B-ALL, which traditionally relied on chemotherapy-based approaches. Inotuzumab ozogamicin is a humanized CD22 monoclonal antibody linked to the cytotoxic agent calicheamicin. CD22 is expressed on leukemic blasts in >90% of ALL patients, and inotuzumab ozogamicin has shown excellent clinical activity even among heavily pretreated relapsed/refractory (R/R) B-ALL patients and elderly B-ALL patients. Clinical trials have shown superior survival with the drug over chemotherapy-based approaches in the first- or second-line salvage therapy for relapsed B-ALL as monotherapy. Currently, new trials are evaluating inotuzumab ozogamicin in the frontline setting in combination-based approaches. In this review, we summarize the preclinical and clinical data of inotuzumab ozogamicin in R/R B-ALL and foresee the future use of this drug in the clinic.Keywords: inotuzumab ozogamicin, CD22, monoclonal antibodies, acute lymphoblastic leukemia, antibody-drug conjugatehttps://www.dovepress.com/inotuzumab-ozogamicin-in-the-treatment-of-relapsedrefractory-acute-b-c-peer-reviewed-article-JBMInotuzumab ozogamicinCD22monoclonal antibodiesacute lymphoblastic leukemiaantibody drug conjugate |
| spellingShingle | Uy N Nadeau M Stahl M Zeidan AM Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia Journal of Blood Medicine Inotuzumab ozogamicin CD22 monoclonal antibodies acute lymphoblastic leukemia antibody drug conjugate |
| title | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia |
| title_full | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia |
| title_fullStr | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia |
| title_full_unstemmed | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia |
| title_short | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia |
| title_sort | inotuzumab ozogamicin in the treatment of relapsed refractory acute b cell lymphoblastic leukemia |
| topic | Inotuzumab ozogamicin CD22 monoclonal antibodies acute lymphoblastic leukemia antibody drug conjugate |
| url | https://www.dovepress.com/inotuzumab-ozogamicin-in-the-treatment-of-relapsedrefractory-acute-b-c-peer-reviewed-article-JBM |
| work_keys_str_mv | AT uyn inotuzumabozogamicininthetreatmentofrelapsedrefractoryacutebcelllymphoblasticleukemia AT nadeaum inotuzumabozogamicininthetreatmentofrelapsedrefractoryacutebcelllymphoblasticleukemia AT stahlm inotuzumabozogamicininthetreatmentofrelapsedrefractoryacutebcelllymphoblasticleukemia AT zeidanam inotuzumabozogamicininthetreatmentofrelapsedrefractoryacutebcelllymphoblasticleukemia |